Semiglutide Results: What the Numbers Actually Say

The Clinical Data — What the STEP Trials Showed

Semaglutide for weight loss is one of the most thoroughly studied obesity treatments in history. The pivotal evidence comes from the STEP (Semaglutide Treatment Effect in People with Obesity) trial program — a series of randomized, placebo-controlled studies enrolling thousands of patients.

STEP-1 (the headline trial) followed 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidities) for 68 weeks. Patients received either 2.4 mg semaglutide weekly or placebo, both alongside lifestyle counseling. The results:

• Average weight loss on semaglutide: 14.9% of body weight
• Average weight loss on placebo: 2.4% of body weight
• Patients losing ≥10% of body weight: 69% (semaglutide) vs 12% (placebo)
• Patients losing ≥15%: 51% vs 5%
• Patients losing ≥20%: 32% vs 2%

For context: pre-semaglutide obesity drugs typically delivered 5-8% weight loss. Bariatric surgery delivers 25-30%. Semaglutide sits squarely between them — meaningful enough to change health outcomes, without surgical risks.

STEP-4: What Happens When You Stop

STEP-4 followed patients who had reached maintenance dose, then randomized them to either continue semaglutide or switch to placebo. The continuing group kept losing weight. The placebo group regained roughly two-thirds of their lost weight within 48 weeks. The conclusion: semaglutide is a long-term treatment, not a temporary fix.

STEP-5: Two-Year Outcomes

Patients staying on semaglutide for 2 years lost an average of 15.2% — almost identical to year 1. The medication maintained effect without diminishing returns. Side effects also declined over time as patients adapted.

Real-World Results vs. Clinical Trials

Trials are controlled environments. Patients get free medication, regular check-ins, and lifestyle coaching. Real-world results are usually a bit less dramatic — but not by much. Recent observational studies in routine clinical practice show:

• Average real-world loss at 12 months: 11-13% of body weight
• Adherence rate: 60-70% of patients still on treatment at 1 year
• Most common reason for stopping: cost/access, not side effects

Translation: in the real world, you can reasonably expect 10-15% body weight loss in your first year — slightly less than trial averages, but still life-changing. Patients who stay consistent with the dose schedule and pair it with basic lifestyle changes tend to land at the higher end of that range.

Beyond the Scale: Other Health Improvements

Weight loss is only part of the picture. Semaglutide drives improvements across nearly every cardiometabolic marker:

• Blood pressure: Average 5-7 mmHg drop in systolic, 3-4 mmHg in diastolic
• HbA1c: 1.0-1.5% reduction in prediabetic and diabetic patients
• Cholesterol: 5-10% drop in LDL, 10-15% drop in triglycerides
• Liver enzymes: Significant improvement in fatty liver markers (ALT, AST)
• Sleep apnea: Many patients reduce or eliminate CPAP use
• Joint pain: Reduced loading + anti-inflammatory effects
• Cardiovascular events: The SELECT trial showed a 20% reduction in major cardiovascular events in overweight/obese patients with established heart disease

Many patients describe the non-scale changes as more important than the weight itself. Sleeping through the night without CPAP, walking up stairs without knee pain, having energy for their kids — these are the wins that don't show up in a "before and after" photo.

What If It's Not Working?

Some patients hit a plateau or feel the medication isn't working as expected. Before concluding that semaglutide isn't for you, work through this checklist with your doctor:

• Are you actually at maintenance dose (2.4 mg)? Many patients stall because they're stuck at 1.0 mg.
• Is your protein intake high enough? At least 0.8g per pound of target weight.
• Are you doing any resistance training? Muscle loss masquerades as plateaus.
• Have you been on the same dose for 8+ weeks without progress?

If everything checks out and you're still stalled, your doctor may consider switching to tirzepatide, increasing the compounded dose, or adding adjunct therapies. Plateaus are solvable — they're not a verdict.